

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listing of the claims in the application:

LISTING OF THE CLAIMS:

Claims 1-53. (canceled)

Claim 54. (amended) A polynucleotide encoding a polypeptide epitope of a B-cell lymphoma surface immunoglobulin antigen useful as a tumor-specific vaccine in a subject with a tumor or at risk of developing a tumor, encoded at least in part by a nucleic acid in the cells of said tumor, and a nucleic acid sequence promoting expression of said polypeptide in a plant cell or plant and a nucleic acid sequence inducing transient replication of said polynucleotide in the cytoplasm, which polypeptide:

(a) includes an epitope or epitopes unique to, or overexpressed by, cells of said tumor, thereby distinguishing said tumor from all other tumors (i) of the same or different histological type, (ii) in said subject or in another member of said subject's species;

(b) is produced in a plant cell or plant that has been transformed or transfected with said nucleic acid derived from said tumor of said subject;

(c) is obtainable from said plant cell or plant in correctly folded form, without a need for denaturation and renaturation and mimics said epitope or epitopes in their native form; and

(d) is capable of inducing an immune response in a mammal, including said subject, so that administration of said polypeptide results in an antibody or cell-mediated immune response to said epitope or epitopes.

Claim 55. (canceled)